Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3022% above fair value
$465.67−1.39 (-0.30%)
Close on Nov 13, 2026Market cap $251.76BP/E 27.0Yield 2.07%
Amgen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Amgen's EPS for the twelve months ending Sep 30, 2026 was $17.25, up 33.3% year over year. For fiscal 2025 it was $14.23, up 88.2% from the year before. Over ten years it grew 4.6% a year on average. The highest annual figure on record is $14.23 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.23 | +88.2% |
| FY2024 | Dec 31, 2024 | $7.56 | -39.5% |
| FY2023 | Dec 31, 2023 | $12.49 | +3.1% |
| FY2022 | Dec 31, 2022 | $12.11 | +17.8% |
| FY2021 | Dec 31, 2021 | $10.28 | -16.5% |
| FY2020 | Dec 31, 2020 | $12.31 | -4.4% |
| FY2019 | Dec 31, 2019 | $12.88 | +2.1% |
| FY2018 | Dec 31, 2018 | $12.62 | +369.1% |
| FY2017 | Dec 31, 2017 | $2.69 | -73.7% |
| FY2016 | Dec 31, 2016 | $10.24 | +13.0% |
| FY2015 | Dec 31, 2015 | $9.06 | +35.2% |
| FY2014 | Dec 31, 2014 | $6.70 | +0.9% |
| FY2013 | Dec 31, 2013 | $6.64 | +20.3% |
| FY2012 | Dec 31, 2012 | $5.52 | +36.6% |
| FY2011 | Dec 31, 2011 | $4.04 | -15.7% |
| FY2010 | Dec 31, 2010 | $4.79 | +6.2% |
| FY2009 | Dec 31, 2009 | $4.51 | +19.6% |
| FY2008 | Dec 31, 2008 | $3.77 | +37.6% |
| FY2007 | Dec 31, 2007 | $2.74 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.08 | +19.4% |
| Q2 FY2026 | Jun 30, 2026 | $4.37 | +64.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.34 | +4.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.46 | +112.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.93 | +13.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.65 | +92.0% |
| Q1 FY2025 | Mar 31, 2025 | $3.20 | – |
| Q4 FY2024 | Dec 31, 2024 | $1.16 | -18.9% |
| Q3 FY2024 | Sep 30, 2024 | $5.22 | +62.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.38 | -46.3% |
| Q1 FY2024 | Mar 31, 2024 | -$0.21 | -104.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.43 | -52.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.22 | -19.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.57 | +4.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.28 | +97.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.00 | -11.0% |
| Q3 FY2022 | Sep 30, 2022 | $3.98 | +40.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.45 | -11.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.68 | -21.9% |
| Q4 FY2021 | Dec 31, 2021 | $3.37 | +10.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.83 | -7.8% |
| Q4 FY2020 | Dec 31, 2020 | $2.76 | -22.7% |
| Q3 FY2020 | Sep 30, 2020 | $3.43 | +7.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.05 | +1.3% |
| Q1 FY2020 | Mar 31, 2020 | $3.07 | +7.3% |
| Q2 FY2019 | Jun 30, 2019 | $3.57 | +2.6% |
| Q1 FY2019 | Mar 31, 2019 | $3.18 | -2.2% |
| Q4 FY2018 | Dec 31, 2018 | $3.01 | – |
| Q3 FY2018 | Sep 30, 2018 | $2.86 | +3.6% |
| Q2 FY2018 | Jun 30, 2018 | $3.48 | +19.6% |
| Q1 FY2018 | Mar 31, 2018 | $3.25 | +16.5% |
| Q4 FY2017 | Dec 31, 2017 | -$5.89 | -327.4% |
| Q3 FY2017 | Sep 30, 2017 | $2.76 | +3.0% |
| Q2 FY2017 | Jun 30, 2017 | $2.91 | +17.8% |
| Q1 FY2017 | Mar 31, 2017 | $2.79 | – |
| Q4 FY2016 | Dec 31, 2016 | $2.59 | – |
| Q3 FY2016 | Sep 30, 2016 | $2.68 | – |
| Q2 FY2016 | Jun 30, 2016 | $2.47 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?